A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study

INTRODUCTION: Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Charytan, Chaim, Manllo-Karim, Roberto, Martin, Edouard R., Steer, Dylan, Bernardo, Marializa, Dua, Sohan L., Moustafa, Moustafa A., Saha, Gopal, Bradley, Charles, Eyassu, Meraf, Leong, Robert, Saikali, Khalil G., Liu, Cameron, Szczech, Lynda, Yu, Kin-Hung P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258588/
https://www.ncbi.nlm.nih.gov/pubmed/34307977
http://dx.doi.org/10.1016/j.ekir.2021.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258588/
https://www.ncbi.nlm.nih.gov/pubmed/34307977
http://dx.doi.org/10.1016/j.ekir.2021.04.007

Ejemplares similares